Cirrhosis Clinical Trials

246 recruitingLast updated: June 17, 2026

There are 246 actively recruiting cirrhosis clinical trials across 44 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3. Top locations include Cleveland, Ohio, United States, London, United Kingdom, Lyon, France. Updated daily from ClinicalTrials.gov.


Cirrhosis Trials at a Glance

246 actively recruiting trials for cirrhosis are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Not Applicable with 80 trials, with the heaviest enrollment activity in Cleveland, London, and Lyon. Lead sponsors running cirrhosis studies include Institute of Liver and Biliary Sciences, India, Assistance Publique - Hôpitaux de Paris, and Northern Jiangsu People's Hospital.

Browse cirrhosis trials by phase

Treatments under study

About Cirrhosis Clinical Trials

Looking for clinical trials for Cirrhosis? There are currently 95 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cirrhosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cirrhosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 246 trials

Recruiting
Phase 3

Bumetanide vs. Furosemide in Cirrhosis

Cirrhosis
Stacy Johnson500 enrolled1 locationNCT06941415
Recruiting
Phase 2

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

Liver Cirrhosis
Boehringer Ingelheim29 enrolled27 locationsNCT07325526
Recruiting

mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis

CirrhosisHepatocellular Carcinoma (HCC)Epigenomics+1 more
Central Hospital, Nancy, France400 enrolled1 locationNCT06778317
Recruiting
Not Applicable

Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis

Liver CirrhosisGastroesophageal Varices Bleeding
Air Force Military Medical University, China648 enrolled1 locationNCT07253389
Recruiting
Not Applicable

EUS-guided Response Assessment to NSBB

Portal Hypertension Related to Cirrhosis
Universitaire Ziekenhuizen KU Leuven24 enrolled1 locationNCT06513195
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled303 locationsNCT06419374
Recruiting
Phase 2

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

CirrhosisCirrhosis, LiverCirrhosis Due to Hepatitis B+5 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)256 enrolled13 locationsNCT05832229
Recruiting

A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

NAFLD - Non-Alcoholic Fatty Liver DiseaseNAFLD and NASHNAFLD Cirrhosis
The Affiliated Hospital of Hangzhou Normal University20,000 enrolled1 locationNCT07241195
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Phase 2

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

Hepatic CirrhosisLiver Fibrosis
AstraZeneca104 enrolled19 locationsNCT07610837
Recruiting
Not Applicable

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Decompensated Liver Cirrhosis
Institute of Liver and Biliary Sciences, India60 enrolled1 locationNCT07002827
Recruiting

Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease

Alcoholic Liver DiseaseAlcoholic CirrhosisSevere alcoholic hepatitis
University Hospital, Lille447 enrolled9 locationsNCT04106518
Recruiting

Austrian PBC Registry

Liver CirrhosisPrimary Biliary CholangitisPortal Hypertension
Medical University of Vienna500 enrolled11 locationsNCT07598669
Recruiting
Phase 4

DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

Cardiometabolic Risk FactorsCirrhosisCirrhotic Cardiomyopathy+1 more
Post Graduate Institute of Medical Education and Research, Chandigarh400 enrolled1 locationNCT07322237
Recruiting

Microplastics, Cirrhosis and Portal Hypertension

CirrhosisPortal Hypertension Related to CirrhosisMicroplastics+3 more
Post Graduate Institute of Medical Education and Research, Chandigarh30 enrolled2 locationsNCT07280390
Recruiting

Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

Liver CirrhosisLiver TransplantationAcute Liver Failure+1 more
University Medical Center Groningen10,000 enrolled2 locationsNCT07585890
Recruiting
Not Applicable

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

Physical InactivityCirrhosis, LiverMuscle Loss+2 more
University of Pennsylvania110 enrolled2 locationsNCT06136221
Recruiting
Phase 1Phase 2

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

CirrhosisAlcohol Use DisorderLiver Disease; Alcohol-Related
Virginia Commonwealth University80 enrolled2 locationsNCT05548452
Recruiting

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

Cirrhosis, LiverDiabetes Mellitus RiskTransplant-Related Disorder+1 more
University of Chicago60 enrolled1 locationNCT06950788
Recruiting
Not Applicable

CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis

Decompensated Cirrhosis
University College, London214 enrolled15 locationsNCT06223893